X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New data from insurers show detriments of copay accumulator adjustment programs

By Katie Koziara  |    April 28, 2021
Commercial health insurers are starting to admit what the biopharmaceutical research industry has been warning for some time: copay accumulator adjustment programs hurt patient outcomes and shift...   Read More

West Virginia becomes the first state to lower patient costs by sharing the savings

By Scott LaGanga  |    April 20, 2021
In a historic moment for patient affordability, last week West Virginia became the first state in the nation to adopt ground-breaking legislation, HB2263, requiring insurers and their PBMs to...   Read More

Nearly 40% of commercially insured patients face half their annual out-of-pocket expenses from just one health care encounter

By Katie Koziara  |    March 2, 2021
A new study published in Health Affairs finds that for nearly 40% of commercially insured patients, half of their annual out-of-pocket expenses for medical treatments come from just one hospital,...   Read More

Top five issues voters want addressed in the administration’s first 100 days

By Mark Keida  |    February 18, 2021
When voters cast their ballots in the 2020 election, they made clear their focus on getting COVID-19 under control and fixing the economy. However, health care was still important to many voters,...   Read More

Insurers shift medicine costs to patients with severe chronic illnesses

By Gabby Migliara  |    February 1, 2021
For many patients with complex and chronic conditions, high out-of-pocket costs for medicines pose a significant challenge. Recent research revealed a broken insurance system that fails to help...   Read More

The latest misleading “poll” on drug pricing

By Brian Newell  |    January 28, 2021
When a front group for insurers and drug cost middlemen promote a poll on drug pricing, everyone’s immediate reaction should include a healthy dose of skepticism. The same is true for a poll from...   Read More

New insulin report highlights how incentives benefit middlemen, harm patients

By Brian Newell  |    January 22, 2021
The Senate Finance Committee has released a new report detailing findings of their investigation into the role that market dynamics play in the pricing of insulins. The report conclusions further...   Read More

Key facts: The final rebate rule will be a positive change for patients

By Tom Wilbur  |    January 19, 2021
While drug middlemen are making billions of dollars in record profits at a time when millions of Americans are facing financial struggles, they are also suing to block the final rebate rule, a...   Read More

Election insights: Voter priorities in the states

By Nick McGee  |    December 17, 2020
In the 2020 election, Americans nationwide cast their ballots with two major issues on their minds – the economy and coronavirus. Health care specific concerns centered on pre-existing conditions...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Date

see all

Subscribe to Email Updates